Secukinumab for Ankylosing Spondylitis in Biologic-Free Patients
Treatments studied
Part of Bones, joints & muscles, Skin clinical trials.
This study is looking at how well secukinumab works for people with ankylosing spondylitis in Korea who have never taken a biologic or JAK inhibitor before. It aims to understand if the drug helps control symptoms over a short period of time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of ankylosing spondylitis (a type of inflammatory arthritis).
- Your disease should be active, meaning you have symptoms like back pain, stiffness, or fatigue.
- You must not have used any biologic drugs (like TNF inhibitors or IL-17 inhibitors) or JAK inhibitors before.
- You need to be between 18 and 40 years old.
- Your diagnosis should have been made within the last 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining two biologic medications (adalimumab and secukinumab) can better relieve symptoms of ankylosing spondylitis, a type of arthritis that affects the spine. It may help if you have not responded well to standard nonsteroidal anti-inflammatory drugs (NSAIDs) and you have active disease.
This study tests the safety of a drug called secukinumab (given as an injection under the skin) for people with axial spondyloarthritis, a type of arthritis that affects the spine and joints. It aims to see if this treatment is safe for adults in India with this condition.
This study tests a new medication (called 608) for adults with active ankylosing spondylitis (AS). It aims to see if the drug can reduce AS symptoms and improve quality of life.
This trial tests a new oral medication called LNK01001 for adults with active ankylosing spondylitis. It aims to reduce pain, stiffness, and inflammation when standard NSAID treatments no longer help.
This study looks at the bacteria living in your body (the microbiome) in people with ankylosing spondylitis and their close family members. Researchers hope to better understand how these bacteria relate to the disease, which may lead to better treatments in the future.
This study compares two types of biologic drugs (IL-17 inhibitors vs. anti-TNF drugs) in people with ankylosing spondylitis (a form of arthritis affecting the spine) who have already tried standard treatments. The goal is to see which drug works better for controlling symptoms.
Hear when a new Ankylosing Spondylitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.